Transcript FP7 - Health Theme (Office document, 2602kB)

EU Framework Programme 7
University of Bristol 4th May 2011
Victoria Brewer
UK National Contact Point – Health Theme (Academia)
International Strategy Manager, Medical Research Council
Agenda
• MRC’s role within FP7
• Funding opportunities within FP7
• 2012 Health Work Programme
• Key points
• Topics by activity area
MRC and FP7
MRC has four roles in FP7:
1. Participant
2. NCP for the Health Theme –
Victoria Brewer
• MRC
leads the PMC Management
delegation at the invitation of
3. Programme
the Department
of Business
Innovation
Committee
(Health)
– Markand Skills
(BIS) Palmer
• Alternative delegates are:
of Health (DH)for
4.• Department
State Representative
Innovative
Medicines
• Technology
Strategy
Board Initiative
– Jill Jones
• Expert group e.g. UKRO
• Joint lead between MRC and BIS
What is FP7
•
Main mechanism used by the European Commission to
fund research across Europe.
•
Two main aims:
1. To strengthen the scientific and technological base
of European industry.
2. To encourage international competitiveness while
promoting research that supports EU policies.
•
How does the EC aim to achieve this?
• Addressing
Pan-European
challenges
• Pooling resources
• Assembling
critical mass
•
Orphan
research
• Supporting research careers and
• Coordinating
national
and regional
• Integration of research
• Enabling
“big
science”
mobility
of research
programmes
• Excellence in research
• Leverage
investment
• Creating
world private
class centres
of
•
Conducting
comparative
research
at
• Addressing Specific Needs excellence
EU level
• EU level competition to increase
• Disseminating research result more
quality and creativity
widely
FP7 Budget
• Seven year funding programme with a budget of around
€50.5 Billion
Cooperation
65%
To date the UK has received 14%
of the overall funding awarded
Ideas
15%
JRC
3%
Capacities
8%
People
9%
Ideas – European Research Council
• € 7.5bn budget
• Managed through the European Research Council (ERC)
• Bottom up/investigator led research
• Research within your own team – no international collaboration
ERC Advanced
Early grants
Grants
•
•
•
Funding: ~ € 2.5
1.5 M for up to 5 year
2-12 years post
“exceptional”
research
PhD at application
leader
UK has received 172*
180* grants to date
• ERC-2010-AdG
ERC-2010-StG call
call -79/427
- 53/266went
wenttotoUK
UKHEI
HEI
(19%)
(20%)
People – Marie Curie Actions
• €4.75bn budget
• Managed through Marie Curie Actions
• Research mobility and career development scheme –inc’
coordination of PhD programmes
• Allows for European and International exchange
• Schemes for individuals or organisations
Organisation
Individual
•• €1.3
Initial
Marie
Curie
Training
Intra-European
Networks (ITNs)
Fellowships
– aimed for
at initial
Career
training
•To date
billion
awarded
of
Development
researchers, first
(IEF)
five
-move
yearsfrom
of researchers'
one EU or FP7
careers.
associated
Projects
• UK share
€300.8
million
=
23%
will
country
be based
to another
aroundfor
a Joint
a duration
Training
of 1-2
Programme
years. focussing on
•
scientific
Marie Curie
and technological
International
knowledge,
Incomingas
Fellowships
well as other(IIF) –
complementary
bring researchers
skills
based
such
outside
as IPR,Europe
research
intomanagement,
an EU Member
entrepreneurship
State or country associated to FP7 for a duration of 1-2 years.
•
Co-funding of Regional, National and International
Programmes (COFUND) - encourage existing or new
regional or national programmes to open up and provide for
trans-national mobility, as well as to reinforce international
programmes.
Cooperation
• € 32.4bn budget
• Top-down research
• EC sets the Research Agenda
• Proposals must be topic specific
• Multiple-disciplinary
• Collaborative research
• MUST be working with European Partners
(or Associated Countries/ target specific countries)
•
3 is a magic number
• SICA – 2x MS/AC & 2x target region(s)
Who is eligible to participate?
• EU-27 – Member States (MS)
Austria, Belgium, Bulgaria ,
Cyprus, Czech Republic,
Denmark, Estonia, Finland,
France, Germany, Greece,
Hungary, Italy, Ireland, Latvia,
Lithuania, Luxemburg, Malta,
Netherlands, Poland, Portugal,
Romania, Slovakia, Slovenia,
Spain, Sweden, UK
• Associated Countries (AC)
Albania*, Bosnia and
Herzegovina *, Croatia*, Faroe
Islands*, FYR, Macedonia*,
Iceland*, Israel*,
Liechtenstein*, Montenegro*,
Norway*, Serbia*, Switzerland,
Turkey*
*except Euratom
Third countries: ICPC
What organisation can participate?
• Participation is open to a wide range of organisations
and individuals:
•
•
•
•
research groups at universities or research institutes
small or medium-sized enterprises (SMEs)
SME associations or groupings
public or governmental administration (local, regional or
national)
• organisations and researchers from third countries
• international organisations
• civil society organisations
• Need to register your organisation with the EC
Cooperation
Health
Food, Agriculture, Fisheries, Biotechnology
Information and Communication
Technologies
Nano-sciences, nano-technologies,
materials and new production technologies
Energy
Environment
€6.1bn
Obesity,
allergies,
€1.9bn
zoonoses and systems
Medication
biology
€9.1bninformation
technologies, activities on
ageing, patient safety and
virtual physiological
human
Biomaterials
for health
€3.5bn
being
application, nanomedicines
and nanotoxicology
€2.4bn
Environment
€1.9bn and Health
Transport
€4.2bn
Socio-economic sciences and the
humanities
€0.6bn
Space
€1.4bn
Security
€1.4bn
2012 Health Work Programme
Research priorities
1.
2.
3.
4.
Active & Healthy Ageing
•
Europe 2020 - Innovation Union  The pilot European Innovation
Partnership on active and healthy ageing
•
5 topics each looking to fund more than 1 proposal, 4x €6m and 1x
€12m
Medical technologies
•
Supporting the “innovation" strategy and reduce the time to market
•
7 topics each looking to fund more than 1 proposal, 6x €6m and 1x
€3m
Rare diseases
•
Build critical mass for research on rare diseases
•
Currently 4 topics and 1 HIP but likely to become 7 topics
Clinical Trials
•
Continue on initiative started in 2011 work programme
•
Improve the quality of clinical trial data in Europe
•
1x Active and Healthy ageing, 2x Rare diseases and 1xDiabetes
(type 1)
2012 Health Work Programme
Key features to look out for..
• Strong SME focus in the majority of call topics:
• SME-targeted  ≥ 30% budget
• SME-focus  ≥ 15% budget
• Majority of call are 2 stage (exceptions CSA and ERA
Net)
Process
2011 WP Deadline
13th Oct 2010
• Outline submission
~ 20th Dec 2010
• Invitation to second stage
10th Feb 2011
• Full proposal submission
~ end April/early May 2011
• Results
2012 Health Work Programme
CLOSED AREAS:
1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN
HEALTH
• 1.1 High-throughput research
• 1.3 Suitability, safety, efficacy of therapies
2. TRANSLATING RESEARCH FOR HUMAN HEALTH
DRAFT
• 2.2.1 Brain and brain-related diseases
• 2.3.1 Anti-microbial drug resistance
Refer
to theepidemics
final
• 2.3.3 Potentially new and
re-emerging
published
• 2.3.4 Neglected infectious
diseases version
• 2.4.1 Cancer
when released
• 2.4.2 Cardiovascular diseases
3. OPTIMISING THE DELIVERY OF HEALTHCARE TO EUROPEAN CITIZENS
• 3.1 Translating the results of clinical research outcome into clinical practice
including better use of medicines, and appropriate use of behavioural and
organisational interventions and new health therapies and technologies
• 3.3 Health promotion and prevention
4. OTHER ACTIONS ACROSS THE HEALTHTHEME
• 4.2 Responding to EU policy needs
The Health Theme
1
Biotechnology,
generic tools
and medical
technologies
for human
health
2
3
Translating
research for
human health
Optimising the
delivery of
healthcare to
European
citizens
4 Emerging policy needs/unforeseen needs
1.2 DETECTION, DIAGNOSIS AND MONITORING
• HEALTH.2012.1.2-1. Development of technologies with
a view to patient group stratification for personalised
medicine applications.
Key points:
• SME-targeted Collaborative Project up to €6m
• One or more proposals can be selected.
• Two-stage call
≥ 30 %
Focus:
• Research and development of technologies  application of
tailored medical intervention in specifically defined patient
group
• Proof of principle highlighted
• Emphasis of data collection and analysis i.e. statistical tool +
quality control around this
• Active inclusion of end users (particular for proof of principle)
1.3 SUITABILITY, SAFETY, EFFICACY OF
THERAPIES
Innovative Medicines Initiative
•
•
Joint EC and EFPIA funding scheme = €2 billion
Research areas in
• Safety
• Efficacy
• Education & training
• Knowledge management
• 4th call Estimated launched in June 2011
• Indicative topics:
– Assessment of drug-induced toxicity in relevant organs –
surrogates for early drug failure
– Enhancing translation in neurological diseases
– European Medical Information Systems
– Stem Cells for drug development and toxicity screening
– Beyond high-throughput screening
– Disease heterogeneity/taxonomy of disease
– Genetic mapping of extreme phenotypes
– Combination therapy development
1.4 INNOVATIVE THERAPEUTIC APPROACHES
AND INTERVENTIONS
Focus = Transplantation
Rationale:
• Clinical demand
• Continuity of successful FP6 projects
• Recent progress in other areas
• Policy developments i.e. DG SANCO
1.4 INNOVATIVE THERAPEUTIC APPROACHES
AND INTERVENTIONS
• HEALTH.2012.1.4-1: Innovative approaches to solid
organ transplantation.
Key points:
• SME-focused Collaborative Project up to €6m
• One or more proposals can be selected.
• Two-stage call
≥ 15 %
Focus:
• Improve the outcome, increase efficiency &/or widen the
scope of solid transplantation
• Clinical focus inc’. Regulatory, safety & immunological aspects
• Improved treatment  improved personal targeting &
tolerance
1.4 INNOVATIVE THERAPEUTIC APPROACHES
AND INTERVENTIONS
• HEALTH.2012.1.4-2: Medical technology for the
transplantation sector and bioartificial organs
Key points:
• SME-targeted Collaborative Project up to €6m
• One or more proposals can be selected.
• Two-stage call
Focus:
• Develop novel tools, techniques & devices for use in
transplantation and in bioartifical organs
• Include cells, tissues or organs
• Clinical/in-patient trial = central to the proposal
• Cover safety & efficacy assessment + regulatory work
≥ 30 %
1.4 INNOVATIVE THERAPEUTIC APPROACHES
AND INTERVENTIONS
• HEALTH.2012.1.4-3: Innovative strategies for
translation of stem cell based therapies in regenerative
medicine.
Key points:
• SME-targeted Collaborative Project up to €6m
• One or more proposals can be selected.
• Two-stage call
•
EU and Australia Cooperation
•
•
•
•
≥ 15 %
EU &
Australia
Australian Partners ~ 50% work carried out in Australia
Joint submission to EC and NHMRC
Australian Partners apply to NHMRC ≠ request EU funds  €6m max
EC contribution to European Team
Max NHMRC contribution = €6m
1.4 INNOVATIVE THERAPEUTIC APPROACHES
AND INTERVENTIONS
• HEALTH.2012.1.4-2 cont’.
Focus:
• Characterisation
• Mechanisms of action and nature of host response(s)
• Quality control of product(s),
• Efficacy and safety in relevant preclinical models
•
•
•
Bridging studies can be included
2 phase project  2nd stage dependent on regulatory approval
• 5 year – review at Yr 3  Yrs 4&5 dependent on approval
of joint regulatory filing
• funds divided equally between the 2 phases
Outcome = Therapeutic products & clinical protocols
developed with industrial partners
1.4 INNOVATIVE THERAPEUTIC APPROACHES
AND INTERVENTIONS
• HEALTH.2012.1.4-4: Targeted nucleic acid delivery as
an innovative therapeutic or prophylactic approach.
Key points:
• SME-targeted Collaborative Project up to €6m
• One or more proposals can be selected.
• Two-stage call
≥ 30 %
Focus:
• Immunotherapy, gene therapy or DNA vaccination, RNA
interference
• Clinical testing carried out throughout of the life time of the
project – inc’. regulatory work
• Preclinical work around safety, immunogenicity, toxicity and
feasibility studies should have already been completed
The Health Theme
1
Biotechnology,
generic tools
and medical
technologies
for human
health
2
3
Translating
research for
human health
Optimising the
delivery of
healthcare to
European
citizens
4 Emerging policy needs/unforeseen needs
2.1 INTEGRATING BIOLOGICAL DATA AND
PROCESSES: LARGE-SCALE DATA GATHERING,
SYSTEMS BIOLOGY
2.1.1 Large-scale data gathering
• HEALTH.2012.2.1.1-1: Clinical utility of -omics for
better diagnosis and treatment of rare diseases.
Key points:
• WAS a High Impact Project – going to broken down into
individual Collaborative Project
Focus:
• New topics = Still TBC
• Likely to cover
• -omics approaches and technologies for molecular
characterisation for a chosen rare disease  new
diagnostics and treatment in clinical settings
• Utilisation of existing databases/biobanks
• Coordination and harmonisation of patient registries
2.1.1 Large-scale data gathering (cont’.)
• HEALTH.2012.2.1.1-2: Validation of -omics-based
biomarkers for diseases affecting the elderly.
Key points:
• SME-targeted Collaborative Project up to €12m
• One or more proposals can be selected.
• Two-stage call
≥ 30 %
Focus:
• Clinical validation already identified -omics based biomarkers
 sensitivity, specificity and predictive power  improved
diagnosis, prognosis, patient stratification and/or treatment
monitoring
• Inc’. statistical models and quality control for data generated
2.1.1 Large-scale data gathering (cont’.)
• HEALTH.2012.2.1.1-3: Statistical methods for collection
and analysis of -omics data.
Key points:
• SME-targeted Collaborative Project up to €6m
• One or more proposals can be selected.
• Two-stage call
≥ 15 %
Focus:
• Improve or develop new statistical models / tools for analysis
of –omic based data
• Open to any –omics based data e.g. genomics, proteomics etc
or particular class of analysis
• Clinical trials excluded
• Must include appropriate training and dissemination activities
2.1 INTEGRATING BIOLOGICAL DATA AND
PROCESSES: LARGE-SCALE DATA GATHERING,
SYSTEMS BIOLOGY
2.1.2 Systems biology
• HEALTH.2012.2.1.2-1: Systems medicine: SME-driven
research applying systems biology approaches to
address medical and clinical needs.
Key points:
• SME-targeted Collaborative Project up to €3m
• One or more proposals can be selected.
• Two-stage call
• Small to minimum consortium sizes
• Project duration up to 2 years
• No intermediate payments or reports
≥ 30 %
2.1.2 Systems biology (cont’.)
• HEALTH.2012.2.1.2-1 cont’.
Focus:
• Development, improvement and application of systems biology
approaches to medical/clinical questions e.g.:
• Re-design of clinical trials by shortening timescale and
costs;
• Development of combinatorial therapies and/or
chronotherapies for complex diseases
• Development of combinatorial biomarkers
• Etc…
•
•
Establish proof-of-concept  demonstrate the potential for
exploitation
Exploitation of results in clinical an/ or industrial sectors
2.1.2 Systems biology (cont’.)
• HEALTH.2012.2.1.2-2: Systems medicine: Applying
systems biology approaches for understanding complex
human diseases and their co-morbidities.
Key points:
• Collaborative Project up to €12m
• One or more proposals can be selected.
• Two-stage call
Focus:
• Integrated multidisciplinary research inc’. pre-clinical and
clinical research  clinicians, biologists computational
scientists, mathematician etc
• Address a clear clinical need  new avenues of understanding
patho-physiology, diagnosis and treatment of complex
diseases
2.1.2 Systems biology (cont’.)
• HEALTH.2012.2.1.2-3: Preparing for the future research
and innovation activities in systems medicine.
Key points:
• Coordination and Support Action (CAS) up to €3m
• Only one proposals can be selected.
• Two-stage call
Focus:
• Promote, support and coordinate research activities in systems
biology across Europe
• Best practice, information and resources of successful
methodological approaches.
• Multidisciplinary training requirements for the next generation
• Promote innovation activities  technology transfer
exploitation
http://ec.europa.eu/research/health/past-events_en.html
2.2 RESEARCH ON THE BRAIN AND RELATED
DISEASES, HUMAN DEVELOPMENT AND
AGEING
2.2.2 Human development and ageing = Primary
focus
Rationale:
• Europe has highest proportion of older people in the world
• Grand challenge of understanding the ageing process
• More targeted geriatric medicines
• Innovation Union partnership – Active and Healthy Ageing
http://ec.europa.eu/research/innovationunion/index_en.cfm?section=active-healthy-ageing
2.2.2 Human development and ageing
• HEALTH.2012.2.2.2-1: Integrative systems biology and
comparative genomics for studying human ageing
and/or most common age-related diseases.
Key points:
• SME-targeted Collaborative Project up to €6m
• One or more proposals can be selected.
• Two-stage call
≥ 30 %
Focus:
• Interactions between genetics, epigenetic and environmental
factors  ageing phenotype in normal and disease conditions
• Computational approaches, comparative genomic studies of
existing data and appropriate modelling
• Can include tools for diagnosis, prognosis and monitoring of
therapies
2.2.2 Human development and ageing (cont’.)
• HEALTH.2012.2.2.2.-2: Investigator-driven clinical trials
for optimisation of management of elderly patients with
multiple diseases.
Key points:
• SME-targeted Collaborative Project up to €6m
• One or more proposals can be selected.
• Two-stage call
≥ 15 %
Focus:
• Compare various treatment regimens in elderly population
treated for multiple diseases
• Clinical trials looking at efficacy and adverse effects of multi
treatment of common age related diseases
2.3 TRANSLATIONAL RESEARCH IN MAJOR
INFECTIOUS DISEASES: TO CONFRONT MAJOR
THREATS TO PUBLIC HEALTH
2.3.0 Cross-cutting
• HEALTH.2012.2.3.0-1: Diagnostics for infectious diseases.
Key points:
• SME-targeted Collaborative Project up to €6m
• One or more proposals can be selected.
• Two-stage call
• No prescribed duration i.e. can be as short as 1-2 years
≥ 30 %
Focus:
• Development and/or validation of diagnostic tests for major
infectious diseases to meet clinical need
• Priority to diseases with unmet medical need i.e. no tests
available & improved testing  better control and management
2.3 TRANSLATIONAL RESEARCH IN MAJOR
INFECTIOUS DISEASES: TO CONFRONT MAJOR
THREATS TO PUBLIC HEALTH
2.3.2 HIV/AIDS, malaria and tuberculosis
• HEALTH.2012.2.3.2-1: Co-infection of HIV/AIDS,
malaria, tuberculosis and/or hepatitis.
Key points:
• Collaborative Project up to €6m
• One or more proposals can be selected.
• Two-stage call
Focus:
• Basic, translation and/or clinical research
• prevention, therapeutic management and prognosis of coinfected patients
• Immunological mechanisms and response to co-infection
• Priority to co-morbidity of relevance to LMIC
2.3.2 HIV/AIDS, malaria and tuberculosis
(cont’.)
• HEALTH.2012.2.3.2-2: Co-morbidity between infectious and
non-communicable diseases.
Key points:
• Collaborative Project up to €6m
• One or more proposals can be selected.
• Two-stage call
Focus:
• Basic, translation and/or clinical research
• prevention, therapeutic management and prognosis of patients
infectious and non-communicable diseases
• Proposals should address:
• Causative links between infectious and non-infectious diseases
• Combination of 3 major poverty related diseases (AIDS, malaria
or TB) or any major poverty related diseases with non-infectious
diseases
2.3.2 HIV/AIDS, malaria and tuberculosis
(cont’.)
• HEALTH.2012.2.3.2-3: Prevention and treatment for
HIV/AIDS, malaria and tuberculosis.
Key points:
• SME-targeted collaborative Project up to €6m
• One or more proposals can be selected.
≥ 15 %
• Two-stage call
• No prescribed duration i.e. can be as short as 1-2 years
Focus:
• Basic or translation research addressing current gaps in
• Prevention and/or treatment of poverty related diseases
(HIV/AIDS, malaria or TB)
• Proposal must inc’:
• Detailed plan for exploitation of end results
• Explore synergies with relevant EU funded initiatives e.g.
European and Developing Countries Clinical Trial
Partnership (EDCTP)
2.3.2 HIV/AIDS, malaria and tuberculosis
(cont’.)
• HEALTH.2012.2.3.2-4: Low-cost interventions for
disease control in resource poor settings.
Key points:
• Collaborative Project up to €3m
• One or more proposals can be selected.
• Two-stage call
Focus:
• Innovative ways to control neglected infectious diseases
and/or malaria  low-cost interventions – immediate impact
• Novel applications of current tools and knowledge  new costeffective solutions
•
•
Combinational therapy, treatment strategies, epidemiology, access
to diagnostics and drugs, operational and implementation research
Inclusion of partners from disease-endemic countries
2.4 TRANSLATIONAL RESEARCH IN OTHER
MAJOR DISEASES
2.4.3 Diabetes and obesity
• HEALTH.2012.2.4.3-1: Innovative approach to manage
diabetes.
Key points:
• SME-targeted Collaborative Project up to €6m
• One or more proposals can be selected.
• Two-stage call
≥ 30 %
Focus:
• Management of diabetes in pre-and/or clinical settings by
validating therapeutic devices or biological therapies
• Attention to safety, bio-compatibility, interoperability and
regulatory aspects  fast and safe uptake of
approaches/technologies
2.4.3 Diabetes and obesity (cont’.)
• HEALTH.2012.2.4.3-2: Investigator-driven clinical trials
for type 1 diabetes research.
Key points:
• Collaborative Project up to €6m
• One or more proposals can be selected.
• Two-stage call
Focus:
• Clinical Trial on type 1 diabetes with focus on paediatric
population  improve glycolic control and/or reduce diabetes
complications
• Inform clinical management of type 1 diabetes
• Excludes pilot studies and systematic reviews
2.4 TRANSLATIONAL RESEARCH IN OTHER
MAJOR DISEASES
2.4.4 Rare diseases (= < 5/10,000)
• HEALTH.2012.2.4.4-1: Preclinical and/or clinical
development of substances with a clear potential as
orphan drugs.
Key points:
• Collaborative Project up to €6m
• One or more proposals can be selected.
• Two-stage call
Focus:
• MUST be EU designated orphan medicinal products
• http://ec.europa.eu/health/documents/communityregister/html/orphreg.htm
• Preclinical studies in models and/or clinical studies
• Excludes cancer and diseases of the nervous system
≥ 30 %
2.4.4 Rare diseases (cont’.)
• HEALTH.2012.2.4.4-2: Observational trials in rare
diseases.
Key points:
• Collaborative Project up to €3m
• One or more proposals can be selected.
• Two-stage call
Focus:
• Rare diseases with no orphan drug available – treated off-label
• Improve clinical management of rare diseases  evidence
based clinical guidance
• Data collection and comparing outcomes of various treatment
regimens
•
•
Evaluation of effectiveness and adverse events
Excludes cancer, infectious diseases and diseases of the
nervous system
2.4.4 Rare diseases (cont’.)
• HEALTH.2012.2.4.4-3: Best practice and knowledge
sharing in the clinical management of rare diseases.
Key points:
• Coordination and Support Action (CAS) up to €2m
• Only one proposals can be selected.
• Two-stage call
Focus:
• Development of a networking platform supporting the
collection of standardised & validated data and exchange of
information providing evidence of best clinical management of
rare diseases
• Identify additional research needs
• Any group of rare diseases
2.4 TRANSLATIONAL RESEARCH IN OTHER
MAJOR DISEASES
2.4.5 Other chronic diseases
• HEALTH.2012.2.4.5-1: Technological approaches to
combating sensory impairments.
Key points:
• SME-targeted Collaborative Project up to €6m
• One or more proposals can be selected.
• Two-stage call
≥ 30 %
Focus:
• Preclinical and clinical testing of novel tools, devices or
therapies' for overcoming sensory disability
• Prevention and treatment strategies, technological
approaches, biological cell based therapies inc’. Stem cells and
development of bio-artificial organs
2.4.5 Other chronic diseases (cont’.)
• HEALTH.2012.2.4.5-2: Biomarkers and diagnostics for
chronic inflammatory diseases of the joints and/or
digestive system.
Key points:
• SME-targeted Collaborative Project up to €6m
• One or more proposals can be selected.
• Two-stage call
Focus:
• Development of improved/novel methodologies  early
diagnosis of chronic inflammatory diseases
• Indicative markers for inflammatory onset and
development & evaluation of intervention therapies
≥ 15 %
The Health Theme
1
Biotechnology,
generic tools
and medical
technologies
for human
health
2
3
Translating
research for
human health
Optimising the
delivery of
healthcare to
European
citizens
4 Emerging policy needs/unforeseen needs
3.2 QUALITY, EFFICIENCY AND SOLIDARITY
OF HEALTHCARE SYSTEMS INCLUDING
TRANSITIONAL HEALTH SYSTEMS
•
HEALTH.2012.3.2-1: Improving the organisation of health
service delivery.
Key
•
•
•
•
points:
Collaborative Project up to €3m
One or more proposals can be selected.
Two-stage call
~ 4 year duration
Focus:
•
Best practice for European health care organisations around,
structure, care processes and performance
•
Areas to be addressed (either one or many):
1. integration of patient care
2. Patient centred care and involvement
3. Skill mix and management of resources (only 1 proposal)
4. Transfer of knowledge into practice ~ span 5 years
3.2 QUALITY, EFFICIENCY AND SOLIDARITY
OF HEALTHCARE SYSTEMS INCLUDING
TRANSITIONAL HEALTH SYSTEMS
•
Key
•
•
•
HEALTH.2012.3.2-2: New methodologies for health
technology assessment.
points:
Collaborative Project up to €3m
One or more proposals can be selected.
Two-stage call
Focus:
•
Develop new and/or improved methodologies for Health
Technology Assessment (HTA)
•
Areas of focus (either or both):
1. Methodologies for addressing the complexity of
interventions
2. Methodologies to assess the efficacy and effectiveness
of technologies
•
Complement previously funded work i.e. EUnetHTA JA
http://www.eunethta.net/
3.4 INTERNATIONAL PUBLIC HEALTH &
HEALTH SYSTEMS
•
HEALTH.2012.3.4-1: Health systems/services
research in low and middle income countries.
Key
•
•
•
•
•
points:
SICA up to €6m
6x ICPC and min 2x EU/AC
One or more proposals can be selected.
Two-stage call
~ 5 years in duration
Focus:
•
Collection, analysis and translation of data into effective
health service planning and policy
•
Focus on (either):
1. Methods to investigate country comparisons and scientific
capacity
2. Human resources for health
3. Knowledge transfer
•
Balanced partnership
The Health Theme
1
Biotechnology,
generic tools
and medical
technologies
for human
health
2
3
Translating
research for
human health
Optimising the
delivery of
healthcare to
European
citizens
4 Emerging policy needs/unforeseen needs
4.1 COORDINATION AND SUPPORT
ACTIONS ACROSS THE THEME
• HEALTH.2012.4.1-1: Network to encourage knowledge
transfer activity in FP-funded health research
(especially in academic and governmental
organisations). CSA €2m
• HEALTH.2012.4.1-2: Training actions linked to
intellectual property rights management and
knowledge transfer. CSA €2m
• HEALTH.2012.4.1-3: Support for Presidency events:
Organisation of supporting actions and events related
to the Presidency of the European Union. CSA €100,000
• HEALTH.2012.4.1-4: Support for the international rare
disease research. CSA €100,000
• HEALTH.2012.4.1-5: Communicating the benefits of
European research to the general public. CSA €100,000
Contacts
• NCP Health (Academia): Victoria Brewer
[email protected]
020 7395 2205
• NCP Health (Industry): Graham Hughes
[email protected]
01302 322633
• NCP ERC & Marie Curie: UK Research Office
[email protected]
00 32 2 230 1535 /5275
Useful websites
• EC website:
http://cordis.europa.eu/fp7/home_en.html
• Connect FP7:
https://ktn.innovateuk.org/web/fp7uk
• UKRO website:
http://www.ukro.ac.uk/
• MRC website – International funding opportunties:
http://www.mrc.ac.uk/Fundingopportunities/Internationalop
portunities/index.htm
Useful websites
• Europe 2020 Strategy
http://ec.europa.eu/resource-efficient-europe/
• Innovation Union http://ec.europa.eu/research/innovationunion/index_en.cfm?pg=intro
• Active and Healthy Ageing
http://ec.europa.eu/research/innovationunion/index_en.cfm?section=active-healthy-ageing
• EDCTP
http://www.edctp.org/
Any questions?